C is for CRISPR
16 November 2016 | By Niamh Louise Marriott, Digital Content Producer
C is for CRISPR - the next instalment of our daily pharmaceutical alphabet bringing you up to date with all the latest news and research of CRISPR technology
List view / Grid view
Articles
B is for Biomarkers
15 November 2016 | By Niamh Louise Marriott, Digital Content Producer
B is for Biomarkers - the next instalment of our daily pharmaceutical alphabet bringing you up to date with all the latest news and research on the subject of biomarkers.
A is for Alzheimer’s disease
14 November 2016 | By Niamh Louise Marriott, Digital Content Producer
A is for Alzheimer's - the first instalment of our daily pharmaceutical alphabet bringing you up to date with all the latest news and research on the fight against this deadly disease
Human endogenous retrovirus expression as targets for multiple sclerosis
9 November 2016 | By Dr Hervé Perron, co-founder and Chief Scientific Officer of GeNeuro
GeNeuro's co-founder and CSO Dr Hervé Perron discusses how a HERV protein could be a target for a novel approach in treating multiple sclerosis...
IVF babies: Easy as 1, 2…3?
3 November 2016 | By Niamh Louise Marriott, Digital Content Producer
The ethics of three parent babies has been widely debated - should it be used to save children from deadly mitochondrial diseases or are scientists "playing God"? Here's everything you need to know to decide...
Predictions for the future: How nanoscience will improve our health and lives
27 October 2016 | By Niamh Louise Marriott, Digital Content Producer
Researchers at UCLA discuss the growing trend of nanoscience, making their scientific predictions for the future of this tech and its global impact...
Rural, poor and sick: The unseen cancer crisis in America
20 October 2016 | By Aaron Yao, PhD, University of Virginia School of Medicine
PhD student Aaron Yao highlights the shocking disparities between rural and urban eastern America and how the odds of cancer survival do not favour the impoverished...
Basel Life Science Week 2016: A “flurry of scientific intellect”
10 October 2016 | By J.T. Kaminski, Director of Technology Services EMEA at IDBS
Drug Target Review brought you all the latest research and development live from the conference. Now read IDBS' J.T. Kaminski's round up of the event...
Vigilin: Could this drug target prevent a heart attack?
27 September 2016 | By ETH Zürich
Scientists identified a protein in liver cells, known as vigilin, which regulates the release of fats from the liver into the bloodstream. Find out more...
Drug Target Review – Issue #3 2016
20 September 2016 | By Drug Target Review
In Issue #3 2016: Flow Cytometry, Enzymes, Imaging, GPCRs, Hit-To-Lead, CNS, Companion Diagnostics, and much more...
Imaging In-Depth Focus 2016
In this Imaging In-Depth Focus: Norman Peterson, from MedImmune/AstraZeneca, looks at the practical application of in vivo optical imaging in biotherapeutic biodistribution analyses. Plus, experts from MRC Technology discuss high-content imaging in drug discovery, and Molecular Devices feature in our Q&A...
Hit-To-Lead In-Depth Focus 2016
20 September 2016 | By Drug Target Review
In this Hit-To-Lead In-Depth Focus: Hit-to-lead in drug discovery; Zebrafish early-life stages as neurological screening and detection tools...
Under the microscope with Joseph Zock, IntelliCyt Corporation
20 September 2016 | By Drug Target Review
Drug Target Review talks to Joseph Zock, Senior Director of Product Management at IntelliCyt Corporation, to find out more about assay developments and future innovations in this area of drug discovery...
Under the microscope with Dr Jeffrey A. Borgia, Rush University Medical Center
Researchers at Rush Medical Center are developing novel diagnostic tests to help guide treatment decisions for patients with non-small cell lung cancer...
Product Showcase: End-to-end next-generation sequencing for clinical diagnostics
20 September 2016 | By Vela Diagnostics
Fuelled by the rapid development of next-generation sequencing (NGS) technologies, it has become apparent that the technology is a key for the identification of genetic variants...